ArticleOncology letters2026
Investigating the roles of microRNAs associated with cancer stem cells, drug resistance, metastasis and recurrence in hepatocellular carcinoma: A systematic review, network analysis and experimental verification.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer stem cells (CSCs) are responsible for drug therapy resistance, recurrence and metastasis in hepatocellular carcinoma (HCC). Certain microRNAs (miRNAs/miRs) are involved in various pathological cancer pathways via their binding interactions with target mRNAs. The objectives of the present study were to explore the potential microRNAs associated with HCC-CSCs, and to investigate their roles in recurrence, metastasis and drug resistance. Initially, a registered systematic review (CRD42024508526; International Prospective Register of Systematic Reviews) identified a group of miRNAs associated with HCC prognosis, and the Coremine Medical data mining tool identified another group of potential miRNAs associated with HCC-CSCs, recurrence, metastasis and drug resistance. Secondly, potential miRNAs that were associated with HCC prognosis, CSCs, recurrence, metastasis and drug resistance were detected by comparing the two groups of miRNAs. Subsequently, the expression levels of a potential miRNA in HCC tissues and its prognostic predictive power were evaluated using the Encyclopedia of RNA Interactomes and Kaplan-Meier plotter online tools. In addition, the expression levels of the target miRNA in Huh7-CSCs and Huh7 cells were measured using reverse transcription-quantitative PCR (RT-qPCR). Finally, the potential biological processes of the miRNA target genes were examined through bioinformatics analysis using the Enrichr database. Briefly, hsa-miR-17-5p was predicted to be associated with stemness, metastasis, recurrence and drug resistance in HCC. Bioinformatics analysis demonstrated that miR-17-5p expression was higher in HCC tissues compared with that in para-tumor tissues and that patients with low miR-17-5p expression demonstrated higher overall survival rates (months). The RT-qPCR results indicated that miR-17-5p expression in Huh7-CSCs was significantly higher compared with that in Huh7 cells. Further bioinformatics analysis suggested that miR-17-5p maintains stemness by targeting hypoxia-inducible factor-1α (HIF1A) and Myc. Additionally, the target genes of miR-17-5p were revealed to be involved in cell fate and metabolic reprogramming pathways. In conclusion, miR-17-5p may be a potential miRNA associated with CSCs, metastasis, recurrence and drug resistance in HCC via cell fate and metabolic reprogramming pathways. miR-17-5p exhibited higher expression in HCC-CSCs compared with that in HCC cell lines, and may target HIF1A and Myc to maintain HCC-CSCs stemness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.